UNLABELLED: This analysis was conducted to assess the effect of high versus lower doses of ibandronate on nonvertebral fractures. The results were adjusted for clinical fracture, age, and bone density. The treatment effect was dose-dependent. Higher doses of ibandronate significantly reduced the risk of nonvertebral fractures more effectively compared with lower doses. INTRODUCTION: The objective of this study was to assess the efficacy of different doses of ibandronate on nonvertebral fractures in a pooled analysis. METHODS: Eight randomized trials of ibandronate were reviewed for inclusion. Alternative definitions of high versus low doses based on annual cumulative exposure (ACE) were explored. A time-to-event analysis was conducted using Kaplan-Meier methodology. Hazard ratios (HR) were derived using Cox regression and adjusted for covariates. RESULTS: Combining higher ACE doses of > or = 10.8 mg (150 mg once monthly, 3 mg i.v. quarterly, and 2 mg i.v. every 2 months) versus ACE doses of 5.5 mg, from two trials, resulted in an HR 0.62 (95% CI 0.396-0.974, p = 0.038). There was a dose-response trend with increasing ACE doses (7.2-12 mg) versus ACE of 5.5 mg. CONCLUSIONS: A dose-response effect on nonvertebral fractures was observed when comparing high with low ACE doses. A significant reduction in nonvertebral fractures was noted when pooling data from trials using ACE doses of > or = 10.8 mg versus ACE < or = 7.2 mg; and with ACE > or = 10.8 mg versus ACE of 5.5 mg (38% reduction). Higher ibandronate dose levels (150 mg monthly or 3 mg i.v. quarterly) significantly reduced nonvertebral fracture risk in postmenopausal women.
RCT Entities:
UNLABELLED: This analysis was conducted to assess the effect of high versus lower doses of ibandronate on nonvertebral fractures. The results were adjusted for clinical fracture, age, and bone density. The treatment effect was dose-dependent. Higher doses of ibandronate significantly reduced the risk of nonvertebral fractures more effectively compared with lower doses. INTRODUCTION: The objective of this study was to assess the efficacy of different doses of ibandronate on nonvertebral fractures in a pooled analysis. METHODS: Eight randomized trials of ibandronate were reviewed for inclusion. Alternative definitions of high versus low doses based on annual cumulative exposure (ACE) were explored. A time-to-event analysis was conducted using Kaplan-Meier methodology. Hazard ratios (HR) were derived using Cox regression and adjusted for covariates. RESULTS: Combining higher ACE doses of > or = 10.8 mg (150 mg once monthly, 3 mg i.v. quarterly, and 2 mg i.v. every 2 months) versus ACE doses of 5.5 mg, from two trials, resulted in an HR 0.62 (95% CI 0.396-0.974, p = 0.038). There was a dose-response trend with increasing ACE doses (7.2-12 mg) versus ACE of 5.5 mg. CONCLUSIONS: A dose-response effect on nonvertebral fractures was observed when comparing high with low ACE doses. A significant reduction in nonvertebral fractures was noted when pooling data from trials using ACE doses of > or = 10.8 mg versus ACE < or = 7.2 mg; and with ACE > or = 10.8 mg versus ACE of 5.5 mg (38% reduction). Higher ibandronate dose levels (150 mg monthly or 3 mg i.v. quarterly) significantly reduced nonvertebral fracture risk in postmenopausal women.
Authors: Pierre D Delmas; Silvano Adami; Cezary Strugala; Jacob A Stakkestad; Jean-Yves Reginster; Dieter Felsenberg; Claus Christiansen; Roberto Civitelli; Marc K Drezner; Robert R Recker; Michael Bolognese; Claire Hughes; Daiva Masanauskaite; Penelope Ward; Philip Sambrook; David M Reid Journal: Arthritis Rheum Date: 2006-06
Authors: Paul D Miller; Michael R McClung; Liviu Macovei; Jacob A Stakkestad; Marjorie Luckey; Bernard Bonvoisin; Jean-Yves Reginster; Robert R Recker; Claire Hughes; E Michael Lewiecki; Dieter Felsenberg; Pierre D Delmas; David L Kendler; Michael A Bolognese; Nicole Mairon; Cyrus Cooper Journal: J Bone Miner Res Date: 2005-03-14 Impact factor: 6.741
Authors: Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas Journal: J Bone Miner Res Date: 2004-03-29 Impact factor: 6.741
Authors: S Adami; D Felsenberg; C Christiansen; J Robinson; R S Lorenc; P Mahoney; K Coutant; R C Schimmer; P D Delmas Journal: Bone Date: 2004-05 Impact factor: 4.398
Authors: R Recker; J A Stakkestad; C H Chesnut; C Christiansen; A Skag; A Hoiseth; M Ettinger; P Mahoney; R C Schimmer; P D Delmas Journal: Bone Date: 2004-05 Impact factor: 4.398
Authors: J T Harrington; L-G Ste-Marie; M L Brandi; R Civitelli; P Fardellone; A Grauer; I Barton; S Boonen Journal: Calcif Tissue Int Date: 2003-12-05 Impact factor: 4.333
Authors: J-Y Reginster; S Adami; P Lakatos; M Greenwald; J J Stepan; S L Silverman; C Christiansen; L Rowell; N Mairon; B Bonvoisin; M K Drezner; R Emkey; D Felsenberg; C Cooper; P D Delmas; P D Miller Journal: Ann Rheum Dis Date: 2005-12-08 Impact factor: 19.103
Authors: Lydia G Schipper; Hanneke W H A Fleuren; Joop P W van den Bergh; Johan R Meinardi; Bart A J Veldman; Cornelis Kramers Journal: Clin Rheumatol Date: 2015-01-29 Impact factor: 2.980
Authors: J-J Body; P Bergmann; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster Journal: Osteoporos Int Date: 2010-05-18 Impact factor: 4.507